DATASPARK/OOREDOO
29.6.2021 02:02:07 CEST | Business Wire | Press release
DataSpark has signed a multi-year strategic deal with communications giant, Ooredoo Group, to automate and standardise their group-wide network planning processes, optimise capital expenditure spending and deliver superior customer experience.
The agreement will see DataSpark introduce its state-of-the-art Smart Network Planning (SNP) product to help establish an advanced analytics platform and capability in network planning across all 10 Ooredoo Group operating companies around the world.
The SNP solution (also referred to as CAPEX Optimizer in some regions) will deliver cost and operational efficiencies for Ooredoo Group’s network expansion investments while ensuring that fast-evolving customer needs are always kept at the centre of decision making.
The product utilises advanced machine learning methodologies to forecast and anticipate network capacity and throughput ahead of time, enabling Ooredoo to direct its capital expenditure in a way that creates the most value for the end customer.
DataSpark Chief Operating Officer, Shaowei Ying, said the partnership is a testament to DataSpark’s ability to provide performance-driven analytics solutions for global telco providers.
“The SNP solution empowers Ooredoo’s operating companies to have an automated, data-driven and customer-centric approach to their radio network capacity planning. It leverages best-in-class technologies that DataSpark developed over the last decade to process data at scale and extract granular insights for decision optimisation,” said Mr Ying. “We welcome this landmark partnership with Ooredoo Group which represents a significant milestone. DataSpark, as part of NCS NEXT, will continue expanding telco-centric analytic solutions and collaborate with telecommunication clients globally.”
The SNP’s application for telcos is founded on several key factors including automated and cost-efficient network planning through customer experience, services and network metrics, and layered analytics to inform accurate network investment decisions.
Ooredoo Group Chief Technology and Information Officer, Nigel Thomas Byrne, said the company’s venture with DataSpark would help ensure visibility and standardisation into network planning activities across the Ooredoo Group. This will also help in sharing network planning best practices across the group and further strengthen the culture of data-driven decision making.
“The insights and recommendations delivered through DataSpark’s SNP solution will provide cost-optimisation and allow us to innovate with our networks, ultimately enhancing the customer experience,” said Mr Byrne. “Our mission to deliver superior service is predicated on high-performance network planning and capacity management, and SNP’s advanced analytics will help us make informed decisions to deliver on this goal.”
DataSpark’s mobility data products are designed to optimise telco network solutions for revenue growth and improve customer satisfaction. DataSpark empowers organisations with mobility intelligence to help maximise the value of their networks and save on capital investment spending. Existing telecommunication clients include Singtel, Optus, Advanced Info Service and Globe Telecom.
About DataSpark: DataSpark are leaders in processing large geospatial temporal mobility data to deliver intelligence on people and places using the highest data privacy standards. Understanding how people move, where they go and what they do enables organisations to make more informed decisions from planning capital expenditure to creating better customer experiences. DataSpark (known as DSpark in Australia) is part of the NCS Group with offices across Australia, Singapore, the Philippines, and Indonesia. For more information, visit dsanalytics.com .
About NCS: NCS is a member of the Singtel Group and the leading information, communications and technology (ICT) service provider with presence in the Asia Pacific region. NCS delivers end-to-end ICT and digital solutions to help governments and enterprises realise business value through digital transformation and the innovative use of technology. NCS invests in NEXT capabilities of digital, cloud, platform and cyber while continuously strengthening its core offerings of applications, infrastructure and engineering. For more information, visit ncs.com.sg .
About Ooredoo: Ooredoo is a leading international communications company delivering mobile, fixed, broadband internet and corporate managed services tailored to the needs of consumers and businesses across markets in the Middle East, North Africa and Southeast Asia. For more information, visit ooredoo.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005022/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
